DE29510462U1 - Fertilitäts-Hemmer - Google Patents
Fertilitäts-HemmerInfo
- Publication number
- DE29510462U1 DE29510462U1 DE29510462U DE29510462U DE29510462U1 DE 29510462 U1 DE29510462 U1 DE 29510462U1 DE 29510462 U DE29510462 U DE 29510462U DE 29510462 U DE29510462 U DE 29510462U DE 29510462 U1 DE29510462 U1 DE 29510462U1
- Authority
- DE
- Germany
- Prior art keywords
- fertility
- fertility inhibitors
- inhibitors
- sexes
- testosterone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000035558 fertility Effects 0.000 title claims description 7
- 239000003112 inhibitor Substances 0.000 title claims description 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
- 229960003604 testosterone Drugs 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 235000005822 corn Nutrition 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 241000272201 Columbiformes Species 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 2
- 206010003495 Aspermia Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Botany (AREA)
- Indole Compounds (AREA)
Description
Die überdurchschnittliche Fertilität(Fruchtbarkeit) der in Stadtgebieten siedelnden Tauben
führt in den betroffenen Städten zu erheblichen Schäden an Kulturdenkmälern und bringt gesund heitliche
Risiken für die Bewohner durch Keimübertragung mit sich.AlIe bisherigen Versuche,
den Taubenbestand zu dezimieren,haben nicht die gewünschte Wirkung erbracht.
Eine spürbare Dezimierung des Taubenbestandes kann nur durch die Hemmung der Fertilität er reicht
werden.Gestagene haben sich als Fertilitäts-Hemmer nicht bewährt,weil nach Absetzen des
Präparats eine Steigerung der Fertilität eintritt und eine irreversible Infertilität nicht erreicht
wird.Um eine dauerhafte Hemmung der Fertilität zu erreichen,bedarf es des Einsatzes einer Substanz,
die bei beiden Geschlechtern eine irreversible Infertilität verursacht.
Als eine der hierfür infrage kommenden Substanzen hat sich Testosteron erwiesen,da es bei den Hähnen
die Spermiogenese bis zur Aspermie herabsetzt und
bei den Hennen jedwede Ovulation unterbindet. Bei längerer Verabreichung kommt es bei beiden Geschlechtern
zu einer irreversiblen Infertilität durch eine hormonelle Kastration.
Claims (1)
- SCHU TZANS P'ROCHEDie Schutzansprüche erstrecken sich auf einen Fertilitäts-Hemmer,bestehend aus dem Wirkstoff Testosteron und gebundenem Maisschrot als Füllmasse.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE29510462U DE29510462U1 (de) | 1995-06-28 | 1995-06-28 | Fertilitäts-Hemmer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE29510462U DE29510462U1 (de) | 1995-06-28 | 1995-06-28 | Fertilitäts-Hemmer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE29510462U1 true DE29510462U1 (de) | 1995-09-14 |
Family
ID=8009849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE29510462U Expired - Lifetime DE29510462U1 (de) | 1995-06-28 | 1995-06-28 | Fertilitäts-Hemmer |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE29510462U1 (de) |
-
1995
- 1995-06-28 DE DE29510462U patent/DE29510462U1/de not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20022788B (en) | Pharmaceutical Compositions Having Appetite Suppressant Activity | |
| IL111647A (en) | Pharmaceutical compositions comprising microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles and their preparation | |
| Reddy et al. | Reversible antifertility action of testosterone propionate in human males | |
| IL112516A0 (en) | Thyroid hormone liquid pharmaceutical composition | |
| HUP9900312A2 (hu) | Humán és állatgyógyászatban alkalmazott növényekből nyert illóolajokon alapuló gyógyszerkészítmények | |
| BR9408513A (pt) | Agente e método para a contracepçÃo hormonal e/ou para o tratamento de acne | |
| Dumont et al. | Evaluation of the efficacy of afoxolaner against two European dog tick species: Dermacentor reticulatus and Ixodes ricinus | |
| WO2003049744B1 (en) | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology | |
| BR0313630A (pt) | Composição para aplicação tópica, sistema para o tratamento de caspa, métodos para o tratamento e/ou prevenção da caspa e da coceira do couro cabeludo e usos de uma combinação sinérgica | |
| EG20772A (fr) | Associations d'un fongicide a groupe azole avec un insecticide a groupe pyrazole pyrrole ou phenylimidazole | |
| CA2248417A1 (en) | Pharmaceutical compositions suitable for use against histomoniasis | |
| US5215748A (en) | Topical preparation and method for suppression of skin eruptions caused herpes simplex virus | |
| DE29510462U1 (de) | Fertilitäts-Hemmer | |
| ES2182983T3 (es) | Formulaciones para la liberacion de peptidos. | |
| AR006578A1 (es) | Composiciones fungicidas que comprenden ciprodinil con miclobutanil o iprodiona y que tienen accion sinergica contra las enfermedades de plantas y unmetodo de proteccion contra las enfermedades | |
| Arya et al. | Lectin staining of rat testis and epididymis: effect of cyproterone acetate and testosterone | |
| Mushir et al. | Pharmacological and therapeutic potential of Oxalis corniculata | |
| Weinstein | Further Studies on the Prophylaxis of Experimental Infections and Intoxications with Various Hormone Preparations | |
| JPS6483024A (en) | Cataplasm for cold | |
| CN1130056A (zh) | 珊瑚姜提取物配制的护发生发液 | |
| DE3626128A1 (de) | Arzneimittel gegen uebelkeit, erbrechen od.dgl. | |
| Christiansen et al. | Dexamethasone-induced parturition in cattle | |
| Aji et al. | Anti‐stress activity of Mitragyna africanus (Willd), stembark extract | |
| Rietschel | A pilot study of pentoxifylline for the prevention of poison ivy/oak reactions. | |
| Valtschanoff et al. | Central release of tracer after noxious stimulation of the skin suggests non-synaptic signaling by unmyelinated fibers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R207 | Utility model specification |
Effective date: 19951026 |
|
| R150 | Utility model maintained after payment of first maintenance fee after three years |
Effective date: 19990127 |
|
| R151 | Utility model maintained after payment of second maintenance fee after six years |
Effective date: 20020712 |
|
| R158 | Lapse of ip right after 8 years |
Effective date: 20031231 |